Some analysts argue for much more to be done for the two-thirds of aboriginals living within Canadian society.

ECONOMIST: Canada

Some analysts argue that this will eventually mean higher costs for customers.

BBC: EU unveils new air passenger rights

Some analysts argue that all subsidies to wind should end and the industry should stand on its own two feet.

BBC: Wind power deadline sees US firms rush to build turbines

Some analysts argue that it would make sense to alter the labelling.

ECONOMIST: Not all triple-A ratings inspire total confidence

Some analysts argue that as Prempro itself only accounts for a small part of the company's earnings, the market is overreacting to the news.

BBC: Drug scare hits Wyeth

Some analysts argue that President Obama would never tap the SPR so soon before the election, out of fear it may appear politically self-serving.

FORBES: Will Obama Pull The Trigger On The Strategic Petroleum Reserve?

All this is plausible, but some analysts argue that the absolute size of a company's research budget matters less than how and where it is deployed.

ECONOMIST: Drug mergers

Some analysts argue that Siemens should have never gone into making handsets because it is a completely different business from its other manufacturing activities, which range from trains to medical equipment and power turbines.

ECONOMIST: Siemens

Some analysts actually argue that Vodafone's pace of acquisitions is so fast that they find it difficult to truly appreciate - or evaluate the company.

BBC: Markets wait for Vodafone

Yet the underlying picture is better, argue some analysts.

WSJ: Upside: Weighing Bargain-Basement Stocks

Aventis' pill, Ketek, does represent a significant advance, but some doctors argue that it isn't that new, and some stock analysts fear that labeling issues could cut the drug's sales.

FORBES: Antibiotic Breakthroughs Fall Short